Twice-weekly dapsone for primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1 infection: efficacy, safety and pharmacokinetic data  by Cruciani, M. et al.
ORIGINAL ARTICLE 
Twice-weekly dapsone for primary prophylaxis against 
Pneztrnocystis cavinii pneumonia in HIV-1 infection: 
efficacy, safety and pharmacokinetic data 
M. Cruciani', E. Bertaxxoni Minelli2, M.  Mirandola', R. Luxzati', M.  Merighi', 
L. Laxxarini', G. Gatti3, S. I/ento', R. Maxxi', M.  Malenu', A. Benini2, 
A. Caxxadori4, G. Piemonte5, D. Bassetti3 and E. Concial 
'Institute of Immunology and Infectious Diseases,Verona, Italy; *Institute of Pharmacology, University 
of Verona, Italy; "First Department of Infectious Diseases, University of Genoa, Italy; 4Bronchoscopy 
Service, Ospedale Civile Maggiore, Borgo Trento, Italy; and 5 L U R M ,  University of Verona, Italy 
Objectives: In this study we evaluated the pharmacokinetics, efficacy and safety of dapsone given 100 mg  twice weekly 
as primary prophylaxis against fneumocystis carinii pneumonia (PCP) in patients with HIV-1 infection. 
Methods: This was a prospective open trial, evaluating a total of 55 HIV-I-infected patients with CD4 cell counts below 
200/mm3 and without previous episodes of PCP. Plasma concentrations of dapsone were determined with high- 
performance liquid chromatography (HPLC). After a mean follow-up of 471 days, the PCP rates per year of observation 
were 6.79%. Discontinuation of treatment as a result of severe side effects was required in  four patients (7.5%). At steady 
state, mean plasma concentrations 24, 72, 96 and 144 h following the administration of dapsone were 1.4650.8, 
0.28t0.20, 0.30t0.21 and 0.37k0.27 mg/L, respectively. Dapsone plasma levels showed a high interpatient variability. 
The values for the pharmacokinetic parameters were comparable to  those described for healthy volunteers. 
Conclusions: The administration of 100 m g  twice weekly of dapsone seems appropriate to maintain effective plasma 
concentrations of the drug and to  prevent PCP with good safety in patients with HIV-I-related immunodeficiency. 
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I NTROD U CTlO N 
Primary prophylaxis is recommended for HIV-infected 
patients at risk of developing a first episode of PCP 
[1,2]. Trimethoprim/sulfamethoxazole (TMP/SMX) is 
the first-choice chemoprophylactic drug in patients 
with CD4+ T-lymphocytes below 200/mm3 [2-41. 
Oral TMP/SMX and aerosolized pentamidine have 
been extensively investigated, and from comparative 
studies TMP/SMX appears to have higher efficacy 
In a recent report, Bozzette et a1 [lo] clarified some 
[ 5-91, 
Corresponding author and reprint requests: 
M. Cruciani, Institute of Immunology and Infectious 
Diseases, University of Verona, Ospedale Civile Maggiore, 
Borgo Trento, 37126 Verona, Italy 
Tel: +45 80 72 390 Fax: +45 83 40 223 
Accepted 9 February 1996 
important aspects of primary prophylaxis of PCP in 
HIV-infected patients. The study suggested that, in 
patients with fewer than 100 CD4+ lymphocytes/mm3, 
prophylaxis with high-dose TMPISMX or high-dose 
dapsone (50 to 100 mg/day) is superior to aerosolized 
pentamidine. However, intolerance turned out to be an 
important issue in patients receiving such a high dose 
of TMP/SMX or dapsone. Previous observations and 
controlled studies suggest that different schedules 
(weekly or twice weekly) of administration of dapsone, 
alone or in combination with pyrimethamine, could be 
effective in PCP prophylaxis. However, so far there are 
few pharniacokinetic data supporting one particular 
regimen [ l  1,121. 
In a prospective open study, we evaluated efficacy 
and safety of twice-weekly dapsone for the primary 
prophylaxis of PCP in HIV-1-infected patients. 
Furthermore, the pharinacokinetics and plasma levels 
of dapsone in patients during prophylaxis were 
investigated. 
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PATIENTS AND METHODS 
The patients were adults with HIV-1 infection without 
previous episodes of PCP. All had CD4' T-lympho- 
cytes below 200/mm" and had not previously received 
prophylaxis against PCP. Patients known to be 
uncompliant were excluded. All participants gave 
informed consent. Serum chemistry, differential blood 
cell count and lymphocyte subpopulations were 
determined a t  least every 3 months. All the patients 
were recruited in the day-care facility of one clinical 
center (Institute of Iinrnunology and Infectious 
Diseases, University of Verona). 
Drug administration 
Eligible patients received oral dapsone (100 Ing twice 
weekly, either Monday and Thursday, or Tuesday and 
Friday). Dapsone was manufactured as wafers of 100 
nig by the hospital pharmacy. The powder was pro- 
vided by Roussel-Uclaf, France. Patients on didanosine 
(ddI) were instructed to take dapsone at least 2 h after 
ddI administration. 
Dapsone plasma level monitoring 
I n  order to study dapsone pharniacokinetics at  steady 
state, six blood samples were obtained from three male 
patients at the following times: 0 (baseline), 2, 4, 24, 48 
and 72 h following drug administration. 
Plasma concentrations obtained from 42 patients 
during follow-up visits were also analyzed. Each of 
these patients had at least one plasma sample processed 
for the purpose of assessing serum levels in the course 
of prophylaxis. Blood samples were collected after a 
mean period of prophylaxig of 6.1 months (range 1 to 
15 months). The samples were obtained by veni- 
puncture at the following time after the last dose: 1.5 
(one patient), 9 (two patients), 13 (three patients), 17 
(one patient), 21 to 22 (six patients), 24 to 26 (nine 
patients), 41 to 48 (five patients), 70 to 72 (seven 
patients) and 95 to 97 (eight patients) h. Blood samples 
were transferred to normal and heparinized tubes and 
centrifuged (1000 2 for 15 min), serum and plasma 
were then immediately frozen at -70 "C until assay. 
Dapsone concentrations were determined by high- 
performance liquid chromatography (HPLC) assay 
[13]. The apparatus consisted of a Gilson pump and a 
spherisorb RP ODs2  column (Spherisorb 5 pm particle 
size, 250 by 4.6 mm, reverse phase) with a UV detector 
(Jasco, model 807) set a t  wavelength 295 nin (0.08 
AUFS).The mobile phase was methanol in KHzP04 
(10.0 nmol/L) 60:40 (v/v) at pH 6.0; the flow rate 
was 1.2 niL/rnin; the standard count was linear in the 
range 0.005 to 50.0 nig/L; the intra-assay and inter- 
assay relative standard deviations were 2% and 3.596, 
respectively. Ihpsoiie pharniacokinetic parameters 
were determined using non-conipartniental methods 
[14] implemented in the software EXCEL 4.0 
(Microsoft). The area under the plasma concen- 
tration-time curve from time 0 to the laTt observed 
concentration (Auc0-1 LAST) was calculated using the 
trapezoidal rule. The AUC from the last observed 
concentration to infinity (AUCtl,,t-r) was calculated as 
G,JK,J, where Cia,, is the last observed concentration 
and Kcl is the elimination rate constant. Plasma 
clearance/bioavailability (Cl) was determined by divid- 
ing the dose per body weight by the area under the 
plasma concentration-time curve from 0 to infinity 
(AUCo-,). The apparent volume of distribution/ 
bioavailability (Vd) was calculated as C1/Kci. Elimina- 
tion half-life (t,,,) was obtained by dividing 0.693 by 
K,J, C,,,, and t,,,,x are at the observed peak concen- 
tration and the time at which the peak concentration 
occurs, respectively. 
Clinical endpoints 
Clinical endpoints were development of PCP, adverse 
reaction to the administered drug and need for blood 
transfusion. PCP episodes were diagnosed on clinical 
and niicrobiological findings (identification of P cavirzii 
in bronchoalveolar lavage fluid). 
Fifty-five patients were evaluated. The characteristics of 
the patients are shown in Table I .  Two patients were 
lost at follow-up. The mean follow-up was 471 f 14.4 
days (median 488, range 20 to 1244). 
Efficacy 
Five patients receiving dapsone ((3.4%) developed PCP. 
PCP occurred after 340, 370, 374, 41 5 and 662 days in 
five patients. No deaths due to PCP were recorded. 
Toxicity 
Severe side effects requiring discontinuation of dapsone 
were observed in four patients (7.5%) during treatment 
with dapsone. 
The more common untoward events were hyper- 
sensitivity reactions (three patients). Another patient 
discontinued prophylaxis because of a severe case of 
dapsone syndrome. Four patients required red cell 
transfusion; however, a clear correlation between the 
given prophylaxis and hematologic toxicity was 
demonstrated in only two patients. The median time 
of discontinuation of prophylaxis was 135 days. 
Pharmacokinetics 
F i p r e  1 shows the plasma concentration-time curves 
obtained from three patients who had serial blood 
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Figure 1 Plasma concentration-time profiles at steady state 
following the administration of dapsone (1 00 nig) to three 
male patients. 
sampling (group A), while Figure 2 shows the data 
obtained from the patients evaluated for serum dapsone 
levels during prophylaxis (group B). Pharmacokinetic 
parameters are summarized in Table 2. C,,,, ranged 
from 1 to 1.3 mg/L and occurred at 2 to 4 h (TmaX) 
following drug administration for patients in group A. 
The plasma concentration in group B ranged from 
0.65 to 2.6 mg/L over the first 24 h after drug 
administration. Considerable interindividual variation 
in drug absorption was observed, peak time ranging 
from 1 to 13 h. After 72, 96 and 144 h the plasma 
concentrations were (meanF SD) 0.28 ? 0.20 rng/L, 
Table 1 Characteristics of the study population at entry 
No. patients (sex) 55 (M44, F11) 
Lost at follow-up 2 
Mean age in years (SD) 32.9 (9.9) 
Concomitant zidovudine therapy (96) 43 (78.1) 
Mean CD4+ count/mm3 (SD) 
Risk factors for HIV 
Intravenous drug users (%) 
Previous AIDS diagnosis (%) 10 (18.1) 
110 (98) 
42 (76) 
Homosexuals (%) 9 (16) 
Others ("A) 4 (7) 
0.30F0.21 mg/L, and 0.37 k 0.27 mg/L, respectively. 
The plasma concentration data and pharmacokinetic 
parameters in the AIDS patient population examined 
are indicative of a high interpatient variability. 
Dapsone levels in patients with PCP 
Plasma dapsone levels were determined in three of the 
five patients who developed PCP; two patients showed 
low plasma levels (0.55 mg/L at  24 h, and 0.29 mg/L 
at >96  h), while a third patient had a plasma level as 
high as 2.6 mg/L 13 h following the last dapsone 
administration. 
DISCUSSION 
A number of studies have investigated a variety of daily 
or intermittent regimens of TMP/SMX in patients 
with HIV-related immunodeficiency. We believe that 
the same interest on the issue of dosing should be 
addressed to dapsone prophylaxis. Data from open and 
comparative studies with dapsone are conflicting 
115-281. Different rates of efficacy and safety have been 
reported, but some of these discrepancies can be 
attributed to type of prophylaxis (primary versus 
secondary), administration schedule and concomitant 
pyrimethamine prophylaxis or antiviral treatment with 
ddI [ 1 1,191. Once-daily administration of 50 to 100 mg 
of dapsone is poorly tolerated, with overall side effects 
ranging from 46% to 75% of patients, although highly 
effective (failure rates 2.1-6.4%) [10,20,24,26]. O n  the 
other hand, once-weekly administration of dapsone is 
better tolerated, with side effects ranging from 2.3% 
to 11%, but less effective (failure rate 8.3-15.2%) 
Table 2 Pharmacohnetic values 
1 1.28 2 17.8 3.05 78.2 
2 1.30 4 40.3 2.30 134.0 
3 1 .oo 4 25.5 2.58 105.0 
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Figure 2 Dapsone stcady-state concentrations In serum in 42 HIV-infectcd patients after oral administration (100 nig twice 
weekly). A= nican values; 0 = female; 0 =male. 
[22,23,25]. Twice-weekly administration of dapsone is 
associated with an acceptable rate of side effects, 
ranging from 2% to 13%, coupled with a good absolute 
or comparative efficacy [17,21,27,28]. A recent trial 
evaluating serum levels of dapsone and pyriinethamine 
in patients receiving 200 rng of dapsone once weekly 
for primary prophylaxis of PCP suggests that this 
prophylactic schedule does not provide serum levels of 
the drug adequate to suppress the parasite during the 
entire weekly dosing interval [12]. An in vitro study has 
indeed demonstrated that dapsone suppresses I;! curinii 
replication at a concentration ofO.l mg/L [29], but this 
effect is lost after 72 h in culture [29]. 
O u r  cumulative data support the use of twice- 
weekly dapsone on pharmacokinetic grounds. In this 
study we determined dapsone pharmacokinetics at  
steady state in three patients and plasma concentrations 
of the drug in 42 patients treated with 100 mg of 
dapsone twice weekly. Serum drug concentrations and 
pharniacokinetic parameters were consistent with 
reported values for healthy volunteers and HIV- 
infected children [30-321. The plasma concentra- 
tion-time data are indicative of a high interpatient 
variability of dapsone pharniacokinetics in the popu- 
lation that we examined. A number of factors may be 
responsible for the observed variability such as sex, 
weight, altered gastrointestinal absorptive function, 
protein binding and metabolism, and interaction 
with concomitantly administered drugs [19,33]. I t  
is note-worthy that dapsone levels a t  72 and 96 h 
following administration were above 0.1 mg/L in 13 
of 15 patients monitored. Thus, for most of the 
patients treated with a 100 mg twice-weekly dosage 
regimen, dapsone levels are expected to be always above 
the in vitro 50% inhibitory concentration for I? curinii 
Although the importance of maintaining high 
serum levels of prophylactic drugs is not completely 
understood, as demonstrated by the experience with 
intermittent TMP/SMX, once-weekly dapsone does 
not seein to guarantee adequate protection [I 21. We 
cannot conclude, according to Lee and coworkers, that 
the therapeutic failure may be ascribed to low levels 
of dapsone. In our study we found sustained plasnia 
concentrations of dapsone in two of the three 
monitored patients who developed PCP, while other 
patients with low plasma levels did not develop PCP. 
However a correlation between blood levels of dapsone 
and clinical efficacy is difficult to establish. We believe 
that these pharmacokinetic data make a contribution to 
the prophylactic strategies and. because of the long 
elimination half-life of dapsone. administration of the 
drug twice weekly should be evaluated on clinical 
grounds. 
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